Resumen
[0001] The present invention contains a fragment (arrangement number 2) of peptide GSE24.2 (arrangement number 1). The polypeptide concerned includes nuclear localizing-ized arrangement if needed about polypeptide which may reduce generation of a free radical, and/or damage over structure of DNA of a cell. The present invention relates to the pharmacological constituent containing the polynucleotide which includes again the arrangement which is coding the above-mentioned polypeptide and a vector, the above-mentioned polypeptide, polynucleotide, and/or a vector. The present invention is a use (for example, disease caused by increase of the oxidant stress to a cellular DNA, and/or damage) of the above-mentioned polypeptide further. It is related with use of the above-mentioned polypeptide in the system engineering and the cell culture for raising the use of the above-mentioned polypeptide for dealing with (for example, vasodilatory movement dysfunction syndrome or congenital Keratotic insufficiency ), or preventing, or the degree of survival of a cell.
Reivindicaciones
1. Polypeptide characterised in that it comprises a fragment of the sequence of peptide GSE24.2 (SEQ ID No. 1) with SEQ ID No. 2 able to reduce production of free radicals and/or damage to the structure of cellular DNA, except when this polypeptide consists of peptide GSE24.2 (SEQ ID No. 1) or a fragment of it with SEQ ID No. 4 (GSE2). 2. Polypeptide according to claim 1 characterised in that it comprises at least a fragment of peptide GSE24.2 selected from at least one of the group composed of: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 5 and SEQ ID No. 6. 3. Polypeptide according to any of the claims 1 and 2 characterised in that in addition to this fragment it comprises at least one nuclear localisation sequence bound to at least one of the carboxyl or amino terminal ends of its amino acid sequence. 4. Polypeptide according to claim 3 characterised in that the nuclear localisation sequence is bound to the carboxyl terminal end of this fragment. 5. Polypeptide according to any of the claims 3 to 4 characterised in that the nuclear localisation sequence is sequence KRKR and/or KKEKKKSK. 6. Polypeptide according to any of the claims 3 to 5 characterised in that it consists of one sequence selected from the group composed of: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13 and SEQ ID No. 14. 7. Polynucleotide characterised in that it codes for a polypeptide defined in any of the claims 1 to 6. 28 8. Expression vector characterised in that it comprises a polynucleotide sequence that codes for a polypeptide defined in any of the claims 1 to 6. 9. Pharmaceutical composition characterised in that it comprises at least a polypeptide defined in any of claims 1 to 6 and/or a polynucleotide of claim 7 and/or expression vector of claim 8. 10. Pharmaceutical composition according to claim 9 characterised in that it further comprises at least one pharmaceutically acceptable adjuvant and/or vehicle. 11. Use of a polypeptide comprising a fragment of the sequence of peptide GSE24.2 (SEQ ID No. 1) with SEQ ID No. 2 able to reduce the production of free radicals and/or damage to the structure of cellular DNA for the preparation of a pharmaceutical composition or medicine for the treatment and/or prevention of a disease and/or disorder caused by an increase in oxidative stress and/or damage to cellular DNA. 12. Use according to claim 11 characterised in that the polypeptide is selected from at least one of the group composed of: SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, and SEQ ID No. 14. 13. Use of a polynucleotide defined in claim 7 for the preparation of a pharmaceutical composition or medicine for the treatment and/or prevention of a disease and/or a disorder caused by an increase in oxidative stress and/or damage to cellular DNA. 14. Use of an expression vector defined in claim 8 for the preparation of a pharmaceutical composition or medicine for the treatment and/or prevention of a disease and/or a disorder caused by an increase in oxidative stress and/or damage to cellular DNA. 29 15. Use of any of the claims 11 to 14 characterised in that the disease or disorder is selected from at least one of the group composed of: congenital dyskeratosis, a neurodegenerative disease, Cri du Chat syndrome, ataxia telangiectasia, Nijmegen breakage syndrome, Bloom syndrome, Werner syndrome, Fanconi anaemia, ulcerative colitis, vascular ageing, arteriosclerosis, preferably atherosclerosis, cancer, Duchenne muscular dystrophy, progeria, light hypersensitivity, genetic instability caused by mutation or external agent, Hutchison-Gilford syndrome, xeroderma pigmentosum, Rothmund-Thomson syndrome, pulmonary fibrosis, rheumatoid arthritis and a disease with chronic inflammation. 16. Use according to claim 15 characterised in that the neurodegenerative disease is selected from at least one of the group composed of: Huntington's disease, Alzheimer's disease, Parkinson's disease, cerebellar ataxia and spinal medulla degeneration. 17. Use of a polypeptide comprising a fragment of the sequence of peptide GSE24.2 (SEQ ID No. 1) with SEQ ID No. 2 able to reduce the production of free radicals and/or damage to the structure of cellular DNA or of the polynucleotide or vector that encodes it in tissue engineering and cell culture for improving the cell viability.
